Zacks Investment Research cut shares of Pharming Group (OTCMKTS:PHGUF) from a buy rating to a hold rating in a report issued on Saturday.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

A number of other research analysts have also commented on PHGUF. ValuEngine lowered shares of Pharming Group from a hold rating to a sell rating in a research note on Friday, December 1st. Roth Capital reiterated a buy rating on shares of Pharming Group in a research note on Wednesday, March 7th.

Pharming Group (PHGUF) opened at $1.50 on Friday. Pharming Group has a 52 week low of $0.30 and a 52 week high of $1.96. The company has a market cap of $897.47, a PE ratio of -13.64 and a beta of 2.50. The company has a quick ratio of 0.99, a current ratio of 1.31 and a debt-to-equity ratio of 11.47.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.